Overview

Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.

Status:
Completed

Trial end date:
2004-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects on the quality of life and BMI of new contraceptives.

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Treatments:

Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Combined
Drospirenone
Drospirenone and ethinyl estradiol combination
Ethinyl Estradiol